Influence of Pneumococcal Vaccines and Respiratory Syncytial Virus on Alveolar Pneumonia, Israel
Daniel M. Weinberger , Noga Givon-Lavi, Yonat Shemer-Avni, Jacob Bar-Ziv, Wladimir J. Alonso, David Greenberg, and Ron Dagan
Author affiliations: Yale School of Public Health, New Haven, Connecticut, USA (D.M. Weinberger); National Institutes of Health, Bethesda, Maryland, USA (D.M. Weinberger, W.J. Alonso); Soroka University Medical Center, Beer-Sheva, Israel (N. Givon-Lavi, Y. Shemer-Avni, D. Greenberg); Ben-Gurion University of the Negev, Beer-Sheva (N. Givon-Lavi, Y. Shemer-Avni, D. Greenberg, R. Dagan); Hadassah University Medical Center, Jerusalem, Israel (J. Bar-Ziv)
Figure 1. . PCV uptake and decline in RCAP incidence 2004–05 through 2011–12, southern Israel. A) Uptake of >2 PCV doses among Bedouin and Jewish children 6–17 months of age. Black line indicates overall uptake; shaded areas show the proportion receiving >2 doses of PCV7 (light gray), >2 doses of PCV13 (dark gray), or >1 doses of PCV7 and 1 dose of PCV13 (medium gray). Dotted line indicates 85% uptake of any PCV. B) Unadjusted incidence rate ratio for RCAP comparing the incidence in each July–June year with the average for 2004–05 through 2007–08. RCAP, radiologically confirmed alveolar pneumonia; PCV, pneumococcal conjugate vaccine; PCV7, 7-valent PCV; PCV13, 13-valent PCV.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.